2 completed. 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 2 | Completed 2 |
Follow PT2385: new trials by email Literature Review of PT2385 trials Research Report on PT2385
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| HIF-2 Alpha Inhibitor PT2385 in Treating Patients With Recurrent Glioblastoma HIF-2alpha Inhibitor PT2385, Pharmacological Study, Laboratory Biomarker Analysis - Recurrent Glioblastoma | Phase 2 | Completed | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 24 | 2017-09-14 | 2022-05-09 |
| MK-3795 (PT2385) for the Treatment of Von Hippel-Lindau Disease-Associated Clear Cell Renal Cell Carcinoma (MK-3795-003) MK-3795 - VHL Gene Mutation, VHL | Phase 2 | Completed | Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) | 4 | 2017-04-24 | 2024-09-24 |
Carcinoma, Renal Cell (1) · Glioblastoma (1) · von Hippel-Lindau Disease (1)
Peloton Therapeutics, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA) (1) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (1)
United States (2)
Roy Strowd, MD (1)
UM1CA137443 (1)